SARS containment
This article was originally published in The Gray Sheet
Executive Summary
April 1FDA guidance recommends that blood donor suitability questions be revised to help gauge potential exposure to Severe Acute Respiratory Syndrome and determine whether donors should be deferred. The interim guidelines, which are expected to result in deferral of at most 0.4% of donors, also advise blood establishments to urge donors that have already given blood to report prior potential SARS exposures so that their blood may be quarantined. FDA is unsure if the virus is transmitted by blood, but the agency will monitor and revise its interim criteria based on their effect on the blood supply and on scientific developments. An informational 2SARS website has been established at the agency...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.